New schizophrenia drug tested in major clinical trial

NCT ID NCT01625000

Summary

This study tested whether a medication called MP-214 could help control symptoms in people experiencing a schizophrenia flare-up. Researchers compared the drug against a placebo in 512 patients over 6 weeks to see if it reduced symptoms and was safe to use. The trial measured changes in overall schizophrenia symptoms using standard rating scales.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    Sapporo, Hokkaido, Japan

  • Study site

    Seoul, South Korea

  • Study site

    Taipei, Taiwan

Conditions

Explore the condition pages connected to this study.